

PRISMA 2020 Checklist

Title: Therapeutic Potential of Green Tea's Epigallocatechin-3-Gallate in Oral Cancer – A Comprehensive Systematic Review of Cellular and Molecular Pathways

PROSPERO Registration: CRD42023484808

Study type: Systematic review of in vitro, in vivo, and clinical evidence on EGCG in oral cancer

The following checklist follows PRISMA 2020 guidelines. Items not applicable to this study (e.g., meta-analysis components) are marked as N/A.

Section and Topic	PRISMA Item	Location where item is reported
Title	Identify the report as a systematic review.	Title page
Abstract	Provide a structured summary including background, objectives, data sources, study eligibility criteria, methods, results, and conclusions.	Abstract section
Introduction	Rationale: Describe the rationale for the review in the context of what is already known.	Introduction, paragraphs 1–3
Objectives	Provide an explicit statement of the objective(s) or question(s) being addressed.	Introduction, last paragraph
Methods	Eligibility criteria: Specify inclusion and exclusion	Methods – Eligibility Criteria section

	criteria and how studies were grouped for synthesis.	
Methods	Information sources: Describe all information sources (e.g., databases, registers) and date last searched.	Methods – Information sources and search strategy
Methods	Search strategy: Present the full search strategy for at least one database.	Methods – Information sources and search strategy
Methods	Selection process: Specify methods used to select studies (screening, data extraction).	Methods – Study Selection
Methods	Data collection process: Specify methods for data extraction from reports.	Methods – Data extraction
Methods	Risk of bias assessment: Describe methods used to assess risk of bias of included studies.	Methods – Quality assessment
Results	Study selection: Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusions.	Results – first paragraph, Figure 1 (PRISMA flow diagram)
Results	Study characteristics: Cite each included study and present its characteristics.	Results – Table 1 and text
Results	Risk of bias in studies: Present assessments of risk of bias for each study.	Results – Quality assessment, Figures 2–3

Results	Results of individual studies: Present summary data and effect estimates.	Results – subsections (EGCG Dose, Mechanistic Pathways, Combination Therapy)
Discussion	Summary of evidence: Summarize main findings including strength of evidence and limitations.	Discussion section
Discussion	Limitations: Discuss limitations of the evidence and review processes.	Discussion – final paragraphs
Discussion	Conclusions: Provide a general interpretation of the results and implications for future research.	Conclusion section
Funding	Describe sources of funding and the role of funders.	Funding Declaration
Competing interests	Declare any competing interests of the authors.	Not applicable (no conflicts declared)
Meta-analysis	Describe synthesis methods, heterogeneity, and results if applicable.	N/A – No quantitative meta-analysis conducted